Neoplasms: Clinical Trials

106,848 trials for Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46886 completed, 17104 unknown, 15705 recruiting, 10084 terminated. 35488 Phase 2, 22846 Not applicable, 20605 Phase 1, 9717 Phase 3, 2180 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 235488Completed 14953, Unknown 4976, Recruiting 4869, Terminated 4708, Active not recruiting 2561, Not yet recruiting 1680, Withdrawn 1519, Suspended 149, Enrolling by invitation 73
Not applicable22846Completed 9984, Unknown 4155, Recruiting 3698, Not yet recruiting 1458, Terminated 1300, Active not recruiting 1236, Withdrawn 740, Enrolling by invitation 196, Suspended 79
Phase 120605Completed 9569, Terminated 3159, Recruiting 2822, Unknown 1900, Active not recruiting 1433, Withdrawn 925, Not yet recruiting 607, Suspended 148, Enrolling by invitation 42
Phase 39717Completed 4295, Unknown 1562, Recruiting 1350, Terminated 916, Active not recruiting 905, Not yet recruiting 394, Withdrawn 240, Suspended 32, Enrolling by invitation 23
Phase 42180Completed 1046, Unknown 498, Recruiting 203, Terminated 172, Not yet recruiting 112, Withdrawn 69, Active not recruiting 61, Enrolling by invitation 12, Suspended 7
Early Phase 11658Completed 529, Unknown 291, Recruiting 283, Terminated 184, Not yet recruiting 130, Withdrawn 111, Active not recruiting 102, Enrolling by invitation 15, Suspended 13

Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Naloxegol in the Prevention of POI After Cystectomy
Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications
Phase 2WithdrawnInstitut Paoli-Calmettes2032-01-012026-10-14
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-05-27
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
(a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment
Not applicableNot yet recruitingAhmadu Bello University892029-03-012026-07-29
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
RNS System Implantation - Glioma, Glioma Intracranial
Not applicableNot yet recruitingMedical College of Wisconsin32028-08-012026-10-13
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer
AI Uro-Cam - Bladder Cancer
Not applicableNot yet recruitingChinese University of Hong Kong602028-07-012026-10-28
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Exercise and dietary recommendations - Ovarian Cancer
Not applicableNot yet recruitingOncare Madrid322028-05-012026-10-08
Mapping Patient Decision-making in Thyroid Cancer
Decision navigation tool - Thyroid Cancer
Not applicableNot yet recruitingUniversity of California, Los Angeles502028-04-012026-07-24
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer
Phase 1 / Phase 2Not yet recruitingCHU de Quebec-Universite Laval5002028-03-012025-03-30
Adaptive Neoadjuvant Therapy for Esophageal Cancer
Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy
Not applicableEnrolling by invitationCancer Hospital Chinese Academy of Medical Science, Shenzhen Center432028-03-012025-05-25
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Improving Clinic Delivery of HIV-related Anal Health Services
PEACHES 2.0 Implementation Strategies - HIV, Gonorrhea
Not applicableNot yet recruitingAlbert Einstein College of Medicine82028-02-012026-10-13
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp
Phase 2Not yet recruitingVejle Hospital1102028-02-012026-04-30
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE
Stepped collaborative care intervention, Enhanced Usual Care - Cancer, Depression
Not applicableNot yet recruitingUniversity of Pittsburgh402028-01-142026-04-09
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer
DCE-MRI - Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression
Not yet recruitingHao Xu4002028-01-012026-02-05
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingGerman Cancer Research Center122028-01-012025-03-14

Showing 20 of 106848. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (13516)  ·  Carcinoma, Non-Small-Cell Lung (7079)  ·  Prostatic Neoplasms (6448)  ·  Colorectal Neoplasms (6118)  ·  Lung Neoplasms (5264)  ·  Pancreatic Neoplasms (3676)  ·  Multiple Myeloma (3667)  ·  Neoplasm Metastasis (3594)  ·  Leukemia, Myeloid, Acute (3585)  ·  Carcinoma, Hepatocellular (3375)  ·  Ovarian Neoplasms (3262)  ·  Melanoma (3200)  ·  Stomach Neoplasms (3175)  ·  Lymphoma (3016)

Broader conditions

Neoplasms by Site (72608)  ·  Neoplasms by Histologic Type (43354)  ·  Digestive System Diseases (22577)  ·  Digestive System Neoplasms (21574)  ·  Hemic and Lymphatic Diseases (19880)  ·  Urogenital Diseases (18866)  ·  Neoplasms, Glandular and Epithelial (18803)  ·  Skin and Connective Tissue Diseases (18638)  ·  Skin Diseases (18288)  ·  Pathological Conditions, Signs and Symptoms (17441)  ·  Urogenital Neoplasms (16611)  ·  Immune System Diseases (15072)  ·  Gastrointestinal Diseases (14973)  ·  Genital Diseases (14766)

Interventions

Cyclophosphamide (3091)  ·  Cisplatin (2951)  ·  Carboplatin (2683)  ·  Radiotherapy (2649)  ·  Paclitaxel (2414)  ·  Gemcitabine (2337)  ·  pembrolizumab (2168)  ·  Bevacizumab (2025)  ·  Docetaxel (1930)  ·  Fluorouracil (1682)  ·  Capecitabine (1614)  ·  Dexamethasone (1599)  ·  Oxaliplatin (1531)  ·  Rituximab (1478)  ·  Doxorubicin (1449)

Sponsors

National Cancer Institute (NCI) (3049)  ·  M.D. Anderson Cancer Center (2386)  ·  Memorial Sloan Kettering Cancer Center (1574)  ·  Sun Yat-sen University (1024)  ·  Fudan University (910)  ·  Mayo Clinic (853)  ·  Novartis Pharmaceuticals (833)  ·  AstraZeneca (814)  ·  Hoffmann-La Roche (755)  ·  Dana-Farber Cancer Institute (711)  ·  Pfizer (658)  ·  University Health Network, Toronto (582)  ·  Massachusetts General Hospital (566)  ·  Washington University School of Medicine (550)  ·  City of Hope Medical Center (545)

Countries

United States (44697)  ·  China (16842)  ·  France (9315)  ·  Italy (6827)  ·  Canada (6821)  ·  United Kingdom (6013)  ·  Spain (6003)  ·  Germany (5856)  ·  South Korea (4710)  ·  Netherlands (3809)  ·  Australia (3723)  ·  Belgium (3629)  ·  Taiwan (3014)  ·  Japan (2649)  ·  Poland (2557)

Results publications

PMID 37185961, PMID 34515338, PMID 31401903, PMID 38979716, PMID 41671463, PMID 33538338, PMID 30207593, PMID 37146227, PMID 34037241, PMID 32499241, PMID 35622074, PMID 40135712, PMID 32632956, PMID 37407274, PMID 39606939, PMID 40812353, PMID 41170811, PMID 41276263, PMID 36648215, PMID 33337539, PMID 34350976, PMID 19097774, PMID 35623069, PMID 38572751, PMID 39863139, PMID 25057165, PMID 26808342, PMID 27238653, PMID 31395089, PMID 28410911, PMID 34398557, PMID 35170751, PMID 34081125, PMID 29522361, PMID 31150573, PMID 35101941, PMID 36306483, PMID 39462179, PMID 40443562, PMID 12049862, PMID 19238148, PMID 20375404, PMID 25651787, PMID 25667295, PMID 32827353, PMID 33270906, PMID 33394722, PMID 40341124, PMID 40550489, PMID 15273542

NIH funding

2023 (760), 2017 (406), 2016 (397), 2018 (383), 2025 (380), 2019 (359), 2015 (347), 2014 (338), P30CA033572 (336), 2009 (274), U10CA032102 (260), P30CA016672 (233), 2008 (232), P30CA015083 (225), P30CA015704 (213)